BioCorRx Applies for NASDAQ Listing

Pharmaceutical Investing

BioCorRx has filed for an application on the NASDAQ Capital Market.

BioCorRx (OTCQB:BICX) has filed for an application on the NASDAQ Capital Market.
As quoted in the press release:

Brady Granier, President, CEO and Director, stated, “Over the past year, we have been advancing our pharmaceutical pipeline and pre-clinical activities, as well as our medication-assisted treatment program. We believe we are well positioned to continue our growth and our plans to list on the Nasdaq Capital Markets further reflects the significant progress we have made over the past year.”
Lourdes Felix, CFO, COO and Director, commented, “We look forward to the prospect of a NASDAQ listing which we believe will enhance BioCorRx’s visibility in the investment community to a larger market and provide for a broader, more diverse base of shareholders.”
The Company must meet the NASDAQ Capital Market listing requirements in order to complete the uplist. In addition to certain financial and shareholder requirements, the Company must also meet Nasdaq governance standards for public companies including a board with a majority of independent directors, meeting NASDAQ standards for the composition and duties of its audit, compensation and nominating committees, having a code of conduct, and holding an annual meeting of stockholders.

Click here to read the full press release.

Source: www.accesswire.com

The Conversation (0)
×